84 related articles for article (PubMed ID: 26317793)
1. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Yang H; Li XD; Zhou Y; Ban X; Zeng TT; Li L; Zhang BZ; Yun J; Xie D; Guan XY; Li Y
Oncotarget; 2015 Sep; 6(28):26079-89. PubMed ID: 26317793
[TBL] [Abstract][Full Text] [Related]
2. Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells
Gao J; Li P
Histol Histopathol; 2024 Apr; 39(4):463-470. PubMed ID: 37334930
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Mediated CtBP1 Gene Editing Enhances Chemosensitivity and Inhibits Metastatic Potential in Esophageal Squamous Cell Carcinoma Cells.
Akhtar J; Imran M; Wang G
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762332
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer.
Cotino-Nájera S; Herrera LA; Domínguez-Gómez G; Díaz-Chávez J
Front Pharmacol; 2023; 14():1287505. PubMed ID: 38026933
[TBL] [Abstract][Full Text] [Related]
5. How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance.
Ciccone V; Morbidelli L; Ziche M; Donnini S
Cancer Drug Resist; 2020; 3(1):26-37. PubMed ID: 35582039
[TBL] [Abstract][Full Text] [Related]
6. A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma.
Huang R; Dai Q; Yang R; Duan Y; Zhao Q; Haybaeck J; Yang Z
Front Oncol; 2022; 12():817916. PubMed ID: 35574327
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.
Grumetti L; Lombardi R; Iannelli F; Pucci B; Avallone A; Di Gennaro E; Budillon A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158962
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms associated with chemoresistance in esophageal cancer.
Lohan-Codeço M; Barambo-Wagner ML; Nasciutti LE; Ribeiro Pinto LF; Meireles Da Costa N; Palumbo A
Cell Mol Life Sci; 2022 Feb; 79(2):116. PubMed ID: 35113247
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.
Liu YP; Zheng CC; Huang YN; He ML; Xu WW; Li B
MedComm (2020); 2021 Sep; 2(3):315-340. PubMed ID: 34766149
[TBL] [Abstract][Full Text] [Related]
10. EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis.
Wang K; Wang Y; Wang Y; Liu S; Wang C; Zhang S; Zhang T; Yang X
Stem Cell Res Ther; 2021 Mar; 12(1):186. PubMed ID: 33726845
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
12. Lnc-MCEI mediated the chemosensitivity of esophageal squamous cell carcinoma via miR-6759-5p to competitively regulate IGF2.
Liu G; Guo W; Chen G; Li W; Cui Y; Qin J; Peng J
Int J Biol Sci; 2020; 16(15):2938-2950. PubMed ID: 33061807
[TBL] [Abstract][Full Text] [Related]
13. Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway.
Liao X; Gao Y; Liu J; Tao L; Xie J; Gu Y; Liu T; Wang D; Xie D; Mo S
Front Oncol; 2020; 10():1756. PubMed ID: 33014864
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic translation initiation factor 5A in the pathogenesis of cancers.
Ning L; Wang L; Zhang H; Jiao X; Chen D
Oncol Lett; 2020 Oct; 20(4):81. PubMed ID: 32863914
[TBL] [Abstract][Full Text] [Related]
15. Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning.
Liu S; Wu J; Xia Q; Liu H; Li W; Xia X; Wang J
Comput Struct Biotechnol J; 2020; 18():1891-1903. PubMed ID: 32774784
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition.
Bao Y; Zhang Y; Lu Y; Guo H; Dong Z; Chen Q; Zhang X; Shen W; Chen W; Wang X
Int J Biol Sci; 2020; 16(5):827-837. PubMed ID: 32071552
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
Guan X; Gu S; Yuan M; Zheng X; Wu J
Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic initiation factor 5A2 and human digestive system neoplasms.
Meng QB; Peng JJ; Qu ZW; Zhu XM; Wen Z; Kang WM
World J Gastrointest Oncol; 2019 Jun; 11(6):449-458. PubMed ID: 31236196
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis.
Lu J; Zhao HW; Chen Y; Wei JH; Chen ZH; Feng ZH; Huang Y; Chen W; Luo JH; Fang Y
Exp Ther Med; 2019 May; 17(5):3741-3747. PubMed ID: 30988760
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
